A Speciality BioPharma Leader

Johanna Mercier, General Manager, BMS UK
Johanna Mercier
General Manager, BMS UK and Ireland

At Bristol-Myers Squibb we are focused on finding and developing innovative medicines and delivering them to patients as quickly and efficiently as possible. In the UK, and around the world, our medicines help millions of people in their fight against serious diseases, in fields such as oncology, virology, cardiovascular disease and immunoscience.

To achieve this we are combining the best elements of a leading-edge biotech company with the resources of a major pharmaceutical organisation, to become a leading Diversified Speciality BioPharma company that focuses on what matters most; our patients, our customers and our people.

At the heart of our strategy are the medicines that give meaningful hope to patients and physicians. Bristol-Myers Squibb’s R&D programme has a strong track record of innovation and productivity and has generated 14 new product approvals in 10 years to treat disease areas such as cancer, serious mental illness, HIV/AIDs, hepatitis B, rheumatoid arthritis and cardiovascular disease.

As well as these existing products, Bristol-Myers Squibb is recognised as having one of the most productive pipelines in the industry. We are currently developing scores of additional investigational medicines which are advancing through the company’s pharmaceutical development programme. Our strategy, which includes innovative alliances, partnerships and acquisitions, further enhances our capability to spread best practice and ultimately improve patient outcomes and access by accelerating the discovery and development of new therapies.

Innovation is a critical element of enabling us to deliver on our Diversified Speciality BioPharma strategy. Our staff and company culture are central to our innovative approach to strive to be dynamic and competitive. In addition, we have also been acknowledged as an industry leader in environment and health and safety management.

Our philanthropic programmes have given new hope to some of the world’s most vulnerable citizens. The Bristol-Myers Squibb Foundation invests in a broad range of programmes aiming to transform the healthcare landscape and address areas of high unmet medical need around the globe.

We believe that what sets us apart is the focus we place on making a difference to the lives of patients who are fighting serious diseases and this continues to be at the core of everything that we do.

Johanna Mercier
General Manager, BMS UK

Date of preparation: May 2015 MLTUK1500052-02

 
 

Key Facts

About Bristol-Myers Squibb, our leadership, businesses and products